莱沃西门丹作为一种试验性通道阻断剂中毒的解药
Jouko M Levijoki1, Matti Kivikko, Piero Pollesello
1Orion Pharma, Espoo, Finland.
莱沃西门丹有效地逆转了海豚中过量服用通道阻断剂引起的负面心脏影响和低血压. 这种敏感剂显著提高了生存率,特别是与化结合使用时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 心血管医学 心血管医学
背景情况:
- 通道阻塞剂 (维拉帕米尔,迪尔提亚泽姆) 可以导致危及生命的低血压和负面的内效应.
- 过量服用通道阻塞剂显著降低了生存率.
- 莱沃西门丹是一种敏感剂,具有无otropic 和血管扩展性质.
研究的目的:
- 评估levosimendan在治疗几内亚猪维拉帕米尔或迪尔提亚泽姆中毒的疗效.
- 评估单独和与化联合使用的levosimendan对血液动力学和生存的影响.
- 为了确定levosimendan和化在逆转通道阻断剂毒性方面是否表现出协同作用.
主要方法:
- 一项随机对照研究涉及104只用维拉帕米尔或迪尔提亚泽姆中毒的试验猪.
- 动物接受了盐水,levosimendan (3疗法),化或levosimendan和化的组合治疗.
- 在中毒后60分钟内监测血液动力学和生存率.
主要成果:
- 莱沃西门丹逆转了维拉帕米尔和迪尔提亚泽姆诱导的负面无otropic 效应和低血压.
- 结合的levosimendan和化在改善血液动力学方面表现出协同效应.
- 莱沃西门丹的剂量依赖性改善了生存率,组合治疗达到高达100%的生存率.
结论:
- 莱沃西门丹是一种有前途的治疗剂,用于通道阻断剂中毒.
- 莱沃西门丹和化的组合显示出作为抗毒剂的显著协同潜力.
- 这项研究支持使用levosimendan和化来管理严重的通道阻断剂过量.
更多相关视频
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
